Literature DB >> 33367818

Treatment and long-term outcome in primary nephrogenic diabetes insipidus.

Sergio C Lopez-Garcia1,2, Mallory L Downie1,2, Ji Soo Kim2, Olivia Boyer3, Stephen B Walsh1, Tom Nijenhuis4, Svetlana Papizh5, Pallavi Yadav5, Ben C Reynolds5, Stéphane Decramer6, Martine Besouw7, Manel Perelló Carrascosa8, Claudio La Scola9, Francesco Trepiccione10, Gema Ariceta11, Aurélie Hummel12, Claire Dossier13, John A Sayer14,15,16, Martin Konrad17, Mandy G Keijzer-Veen18, Atif Awan19, Biswanath Basu20, Dominique Chauveau21, Leire Madariaga22, Linda Koster-Kamphuis23, Mónica Furlano24, Miriam Zacchia10, Pierluigi Marzuillo25, Yincent Tse26, Ismail Dursun27, Ayse Seda Pinarbasi27, Despoina Tramma28, Ewout J Hoorn29, Ibrahim Gokce30, Kathleen Nicholls31,32, Loai A Eid33, Lisa Sartz34, Michael Riordan19, Nakysa Hooman35, Nikoleta Printza36, Olivier Bonny37, Pedro Arango Sancho38, Raphael Schild39, Rajiv Sinha40, Stefano Guarino25, Victor Martinez Jimenez41, Lidia Rodríguez Peña42, Hendrica Belge43, Olivier Devuyst44, Tanja Wlodkowski45, Francesco Emma46, Elena Levtchenko47, Nine V A M Knoers48,49, Daniel G Bichet50, Franz Schaefer45, Robert Kleta1,2, Detlef Bockenhauer1,2.   

Abstract

BACKGROUND: Primary nephrogenic diabetes insipidus (NDI) is a rare disorder and little is known about treatment practices and long-term outcome.
METHODS: Paediatric and adult nephrologists contacted through European professional organizations entered data in an online form.
RESULTS: Data were collected on 315 patients (22 countries, male 84%, adults 35%). Mutation testing had been performed in 270 (86%); pathogenic variants were identified in 258 (96%). The median (range) age at diagnosis was 0.6 (0.0-60) years and at last follow-up 14.0 (0.1-70) years. In adults, height was normal with a mean (standard deviation) score of -0.39 (±1.0), yet there was increased prevalence of obesity (body mass index >30 kg/m2; 41% versus 16% European average; P < 0.001). There was also increased prevalence of chronic kidney disease (CKD) Stage ≥2 in children (32%) and adults (48%). Evidence of flow uropathy was present in 38%. A higher proportion of children than adults (85% versus 54%; P < 0.001) received medications to reduce urine output. Patients ≥25 years were less likely to have a university degree than the European average (21% versus 35%; P = 0.003) but full-time employment was similar. Mental health problems, predominantly attention-deficit hyperactivity disorder (16%), were reported in 36% of patients.
CONCLUSION: This large NDI cohort shows an overall favourable outcome with normal adult height and only mild to moderate CKD in most. Yet, while full-time employment was similar to the European average, educational achievement was lower, and more than half had urological and/or mental health problems.
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  AQP2; AVPR2; chronic kidney disease; flow uropathy; nephrogenic diabetes insipidus

Year:  2020        PMID: 33367818     DOI: 10.1093/ndt/gfaa243

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  2 in total

Review 1.  Brain dysfunction in tubular and tubulointerstitial kidney diseases.

Authors:  Davide Viggiano; Annette Bruchfeld; Sol Carriazo; Antonio de Donato; Nicole Endlich; Ana Carina Ferreira; Andreja Figurek; Denis Fouque; Casper F M Franssen; Konstantinos Giannakou; Dimitrios Goumenos; Ewout J Hoorn; Dorothea Nitsch; Alberto Ortiz; Vesna Pešić; Daiva Rastenyté; Maria José Soler; Merita Rroji; Francesco Trepiccione; Robert J Unwin; Carsten A Wagner; Andrzej Wieçek; Miriam Zacchia; Carmine Zoccali; Giovambattista Capasso
Journal:  Nephrol Dial Transplant       Date:  2021-12-28       Impact factor: 5.992

2.  Clinical and Functional Characterization of a Novel Mutation in AVPR2 Causing Nephrogenic Diabetes Insipidus in a Four-Generation Chinese Family.

Authors:  Shusen Guo; Shimin Wu; Zhuxi Li; Lianjing Huang; Di Zhan; Cai Zhang; Xiaoping Luo
Journal:  Front Pediatr       Date:  2021-12-09       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.